Partners HealthCare CEO to retire

Amy Baxter | | Health Exec | Management
woman-3187087_960_720.jpg

David F. Torchiana, MD, CEO of Boston-based Partners HealthCare, has announced his plans to retire, The Boston Globe reported. Partners HealthCare is a not-for-profit healthcare system hospital, which includes Brigham and Women’s Hospital and Massachusetts General Hospital as its founding members.

Torchiana told the Partners board that he plans to retire at the end of April, according to a statement to all employees from Scott Sperling, chair of the Partners board of directors.

“This is something that I know Torch has been contemplating for some time,” Sperling wrote. “Torch has been a valued leader, and he has led this organization in a thoughtful and effective manner.”

The Partners board will work over the next few weeks on a search process to replace the outgoing CEO.

Torchiana was appointed CEO of Partners in 2015 after serving as chairman and CEO of Massachusetts General Physicians Organization. Prior to that, he was a cardiothoracic surgeon at MGH.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.